Advanced Bifurcation Systems to Sponsor XIII European Bifurcation Club Meeting
(Thomson Reuters ONE) -
LOS ANGELES, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Advanced Bifurcation Systems
("ABS" or the "Company"), a clinical stage medical device company developing an
innovative stenting platform which overcomes the limitations of current
approaches for the treatment of bifurcation lesions in coronary angioplasties,
today announced that the Company will be a sponsor of the XIII European
Bifurcation Club (www.bifurc.net) meeting at the Casa Das Artes in Porto,
Portugal on Friday, October 13th and Saturday, October 14th, 2017. Dr. Mehran
Khorsandi, the Company's co-founder, chairman and chief medical officer will
make a presentation entitled "Bifurcations Made Easy" at the conference.
"Our platform based technology is unlike anything on the market today. We have
put extensive patent protection in place and are working with key institutions
and KOL's to advance our program as we move forward to commercialize the
technology and pursue regulatory approval," commented CEO Charles Laverty.
Advanced Bifurcation Systems, through its novel Mother/Daughter ("MD") platform,
has complete coverage for all lesions regardless of branch angle, size, plaque
burden or location. This single system addresses both the main and side branch,
and is mechanically fail-safe and self-aligning for perfect placement.
Dr. Mehran Khorsandi commented, "We have really worked hard to perfect our
technology and believe that when we commercialize our product more
interventional cardiologists will be comfortable doing complex bifurcations.
Our unique technology enables assembly of a bifurcating stent at the carina,
regardless of angles, sizes or plaque burden. We expect that our platform,
which has been tested in 10 patients to date, will require limited training,
greatly reduce procedure times and improve clinical outcomes."
About Advanced Birfurcation Systems
Advanced Bifurcation Systems ("ABS") is a clinical stage medical device company
developing an innovative stenting platform for simple treatment of all
bifurcation lesions in coronary angioplasties. ABS has developed a novel
technology which overcomes the limitations of current approaches while
simplifying the procedure. The Company's groundbreaking system consists of
numerous differentiating features, including a unique modular independently
movable dual-catheter system for provisional side-branch stenting as well as
full bifurcation stenting with a proprietary crimping technology allowing for
partial crimping of the main stent. For more information, go
to www.advancedbifurcation.com.
About EBC 2017
The European Bifurcation Club is an organization of European thought leaders in
the treatment of coronary bifurcation lesions. The group holds an annual
meeting to interact with the medical industry on the development of new
concepts, processes and devices as well as to give scientific credibility to new
clinical and technological projects.
Contact:
Advanced Birfurcation Systems
Charles Laverty
Chief Executive Officer
charles_laverty(at)advancedbifurcation.com
(949)432-4824
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Advanced Bifurcation Systems via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 18.09.2017 - 13:55 Uhr
Sprache: Deutsch
News-ID 560254
Anzahl Zeichen: 3822
contact information:
Town:
Aliso Viejo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 185 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Advanced Bifurcation Systems to Sponsor XIII European Bifurcation Club Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Advanced Bifurcation Systems (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).